DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
SODIUM 2,2-DIMETHYLBUTYRATE
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; beta-Thalassemia
Unknown
SODIUM 2,2-DIMETHYLBUTYRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
XKM99SPB5I
Molecule Type:
Small molecule
Molecular Formula:
C6H11NaO2
Molecular Weight:
138.14
AlogP:
1.51
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
XBD173
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
XBD173
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
R-333
2
Small molecule
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Tyrosine-protein kinase JAK3 inhibitor
R-333
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SITAMAQUINE
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis
Unknown
SITAMAQUINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5AIJ4TGC6B
Molecule Type:
Small molecule
Molecular Formula:
C21H33N3O
Molecular Weight:
343.52
AlogP:
4.87
PSA:
37.39
HBD:
1.0
HBA:
#RotB:
11.0
Source:
TOLPERISONE
2
Small molecule
Investigational
Unknown
Unknown
Muscle Spasticity; Arthralgia; Myalgia
Unknown
TOLPERISONE
×
Maximum Phase:
2
First Approval:
None
UNII:
F5EOM0LD8E
Molecule Type:
Small molecule
Molecular Formula:
C16H23NO
Molecular Weight:
245.37
AlogP:
3.3
PSA:
20.31
HBD:
0.0
HBA:
#RotB:
4.0
Source:
PLACULUMAB
2
Antibody
Investigational
Unknown
Unknown
Sciatica; Arthritis, Rheumatoid
TNF-alpha inhibitor
PLACULUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
S80W9W569L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MRG-201
2
Oligonucleotide
Investigational
Unknown
Unknown
Unknown
Unknown
MRG-201
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENRASENTAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Endothelin receptor ET-A antagonist
ENRASENTAN
×
Maximum Phase:
2
First Approval:
None
UNII:
QG16H8A6ZH
Molecule Type:
Small molecule
Molecular Formula:
C29H30O8
Molecular Weight:
506.55
AlogP:
4.56
PSA:
103.68
HBD:
2.0
HBA:
#RotB:
10.0
Source:
DOCOSAPENTAENOIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Substance-Related Disorders
Unknown
DOCOSAPENTAENOIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
NS3OZT14QT
Molecule Type:
Small molecule
Molecular Formula:
C22H34O2
Molecular Weight:
330.51
AlogP:
6.77
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
AMELPARIB DIHYDROCHLORIDE DIHYDRATE
2
Unknown
Investigational
Unknown
Unknown
Stroke; Ischemic Stroke
Unknown
AMELPARIB DIHYDROCHLORIDE DIHYDRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
H15GT9J2LB
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CARICOTAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular
Unknown
CARICOTAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
MC09H30MFS
Molecule Type:
Small molecule
Molecular Formula:
C8H11N3O2
Molecular Weight:
181.19
AlogP:
-0.94
PSA:
89.42
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BL-1020
2
Small molecule
Investigational
Unknown
Unknown
Psychotic Disorders; Schizophrenia
Unknown
BL-1020
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H34Cl2N4O2S
Molecular Weight:
525.55
AlogP:
4.23
PSA:
62.04
HBD:
1.0
HBA:
#RotB:
10.0
Source:
AEE-788
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Glioblastoma; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
AEE-788
×
Maximum Phase:
2
First Approval:
None
UNII:
F9JLR95I3I
Molecule Type:
Small molecule
Molecular Formula:
C27H32N6
Molecular Weight:
440.6
AlogP:
4.94
PSA:
60.08
HBD:
2.0
HBA:
#RotB:
7.0
Source:
DIRIDAVUMAB
2
Antibody
Investigational
Unknown
Unknown
Influenza, Human; Orthomyxoviridae Infections
Hemagglutinin inhibitor
DIRIDAVUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
JFC86A9HL9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEPILAMIDE FUMARATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
TEPILAMIDE FUMARATE
×
Maximum Phase:
2
First Approval:
None
UNII:
KOS9TZ09CM
Molecule Type:
Small molecule
Molecular Formula:
C11H17NO5
Molecular Weight:
243.26
AlogP:
0.13
PSA:
72.91
HBD:
0.0
HBA:
#RotB:
6.0
Source:
IMD-1041
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
IMD-1041
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SETOGEPRAM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SETOGEPRAM
×
Maximum Phase:
2
First Approval:
None
UNII:
879OVM0Y1S
Molecule Type:
Small molecule
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
AlogP:
3.05
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
6.0
Source:
TOPIROXOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hyperuricemia
Xanthine dehydrogenase inhibitor
TOPIROXOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
0J877412JV
Molecule Type:
Small molecule
Molecular Formula:
C13H8N6
Molecular Weight:
248.25
AlogP:
1.8
PSA:
91.14
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PF-05212377
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
PF-05212377
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
POL6326
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
POL6326
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DHAP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
DHAP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEPATUXIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Adenocarcinoma
Epidermal growth factor receptor erbB1 inhibitor
DEPATUXIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W984C353CG
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BRIVOLIGIDE
2
Unknown
Investigational
Unknown
Unknown
Pain
Unknown
BRIVOLIGIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
O32A9ET2M7
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVISCUMINE
2
Protein
Investigational
Unknown
Unknown
Melanoma
Unknown
AVISCUMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
4B18YVW82N
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOREFORANT TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Arthritis, Rheumatoid; Asthma; Psoriasis
Unknown
TOREFORANT TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
HSV17TLD9C
Molecule Type:
Small molecule
Molecular Formula:
C50H70N12O6
Molecular Weight:
935.19
AlogP:
4.48
PSA:
69.73
HBD:
2.0
HBA:
#RotB:
6.0
Source:
AZD-8871
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
AZD-8871
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRAXOPRODIL
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Parkinson Disease; Stroke
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
TRAXOPRODIL
×
Maximum Phase:
2
First Approval:
None
UNII:
UTC046R5HM
Molecule Type:
Small molecule
Molecular Formula:
C20H25NO3
Molecular Weight:
327.42
AlogP:
2.8
PSA:
63.93
HBD:
3.0
HBA:
#RotB:
4.0
Source:
GLPG-0974
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative
Free fatty acid receptor 2 antagonist
GLPG-0974
×
Maximum Phase:
2
First Approval:
None
UNII:
X7REK61AIS
Molecule Type:
Small molecule
Molecular Formula:
C25H25ClN2O4S
Molecular Weight:
485.01
AlogP:
5.05
PSA:
77.92
HBD:
1.0
HBA:
#RotB:
8.0
Source:
HBM9161
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HBM9161
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
C-1311
2
Small molecule
Investigational
Unknown
Unknown
Unknown
DNA topoisomerase II inhibitor
C-1311
×
Maximum Phase:
2
First Approval:
None
UNII:
MZ4Y5H4OAB
Molecule Type:
Small molecule
Molecular Formula:
C20H22N4O2
Molecular Weight:
350.42
AlogP:
2.9
PSA:
69.87
HBD:
2.0
HBA:
#RotB:
6.0
Source:
HEMIN
2
Small molecule
Investigational
Unknown
Unknown
Coproporphyria, Hereditary; Myelodysplastic Syndromes; Pancreatitis; Porphyria, Acute Intermittent; Porphyrias
Unknown
HEMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
743LRP9S7N
Molecule Type:
Small molecule
Molecular Formula:
C34H32ClFeN4O4
Molecular Weight:
651.95
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LY2624803
2
Small molecule
Investigational
Unknown
Unknown
Sleep Initiation and Maintenance Disorders
Histamine H1 receptor antagonist
LY2624803
×
Maximum Phase:
2
First Approval:
None
UNII:
63J9EQ81YC
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACT-709478
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy, Reflex
Voltage-gated T-type calcium channel blocker
ACT-709478
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z7U1U8Z9E
Molecule Type:
Small molecule
Molecular Formula:
C22H18F3N5O
Molecular Weight:
425.41
AlogP:
3.97
PSA:
83.6
HBD:
1.0
HBA:
#RotB:
6.0
Source:
DAGROCORAT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Glucocorticoid receptor modulator
DAGROCORAT
×
Maximum Phase:
2
First Approval:
None
UNII:
OPM23UN90U
Molecule Type:
Small molecule
Molecular Formula:
C29H29F3N2O2
Molecular Weight:
494.56
AlogP:
6.16
PSA:
62.22
HBD:
2.0
HBA:
#RotB:
4.0
Source:
FIPAMEZOLE
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Adrenergic receptor alpha-2 antagonist
FIPAMEZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
T5RCK09KHV
Molecule Type:
Small molecule
Molecular Formula:
C14H15FN2
Molecular Weight:
230.29
AlogP:
3.0
PSA:
28.68
HBD:
1.0
HBA:
#RotB:
2.0
Source:
1
2
…
174
175
176
177
178
179
180
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA